Outcomes in COVID-19 XAV-19 studies

All studies   Mortality   Ventilation   ICU   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -45% 2 667 Improvement, Studies, Patients Relative Risk Mortality -45% 2 667 Ventilation -106% 1 388 ICU admission -5% 1 388 Progression -9% 2 626 RCTs -45% 2 667 RCT mortality -45% 2 667 Peer-reviewed -90% 1 388 Early -1% 1 279 Late -90% 1 388 XAV-19 for COVID-19 c19early.org November 2025 FavorsXAV-19 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 mortality results c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ POLYCOR Gaborit (DB RCT) -106% 2.06 [1.07-3.96] 26/199 12/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.03 Late treatment -106% 2.06 [1.07-3.96] 26/199 12/189 106% higher risk All studies -106% 2.06 [1.07-3.96] 26/199 12/189 106% higher risk 1 XAV-19 COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.03 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ POLYCOR Gaborit (DB RCT) -5% 1.05 [0.71-1.55] 42/199 38/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.82 Late treatment -5% 1.05 [0.71-1.55] 42/199 38/189 5% higher risk All studies -5% 1.05 [0.71-1.55] 42/199 38/189 5% higher risk 1 XAV-19 COVID-19 ICU result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.82 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 serious outcomes c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 Randomized Controlled Trials c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] 5/139 5/140 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Early treatment -1% 1.01 [0.30-3.40] 5/139 5/140 1% higher risk POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -45% 1.45 [0.65-3.21] 15/338 10/329 45% higher risk 2 XAV-19 COVID-19 RCT mortality results c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk All studies -90% 1.90 [0.66-5.45] 10/199 5/189 90% higher risk 1 XAV-19 COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Effect extraction pre-specified(most serious outcome) Favors XAV-19 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EUROXAV Poulakou (DB RCT) -1% 1.01 [0.30-3.40] death 5/139 5/140 Improvement, RR [CI] Treatment Control EUROXAV Poulakou (DB RCT) -34% 1.34 [0.58-2.88] progression 12/117 9/121 POLYCOR Gaborit (DB RCT) -90% 1.90 [0.66-5.45] death 10/199 5/189 POLYCOR Gaborit (DB RCT) 5% 0.95 [0.19-4.65] death 3/199 3/189 POLYCOR Gaborit (DB RCT) -106% 2.06 [1.07-3.96] ventilation 26/199 12/189 POLYCOR Gaborit (DB RCT) -5% 1.05 [0.71-1.55] ICU 42/199 38/189 POLYCOR Gaborit (DB RCT) -5% 1.05 [0.75-1.47] progression 53/199 48/189 XAV-19 COVID-19 outcomes c19early.org November 2025 Favors XAV-19 Favors control